锁骨下/腋动脉入路自膨胀式经导管主动脉瓣置换术的结果与经股动脉入路相当
该研究基于CoreValve美国关键性试验项目,将202例经锁骨下/腋动脉(SCA)入路行经导管主动脉瓣置换术(TAVR)的患者与经股动脉(TF)入路患者进行倾向性匹配分析。结果显示SCA-TAVR的主要并发症和死亡率与TF-TAVR相当,SCA应作为TAVR的首选次要入路。
要点
- SCA入路TAVR的主要并发症和死亡率与TF入路相当。
- SCA组术后球囊扩张较少(17.9% vs 26.7%,p=0.03),全身麻醉更多(99.0% vs 89.6%,p<0.001)。
- SCA应作为TF不适合患者的首选次要入路。
核心结论
- SCA-TAVR的主要并发症和死亡率与TF-TAVR相当。
- SCA应作为TAVR的首选次要入路,因为其手术和临床结果与TF-TAVR相当,且适用于大多数非TF候选患者。
研究设计与样本
- 来自CoreValve美国关键性试验项目的202例SCA入路患者与TF入路患者进行倾向性匹配分析。
主要发现
- 匹配成功,除SCA组现在或过去吸烟者更多(79.2% vs 61.4%,p<0.001)和需要输血的贫血患者更少(18.5% vs 27.5%,p=0.04)外,基线无显著差异。
- SCA组从入组到手术时间显著更长(8.6 ± 19.1 vs 5.3 ± 6.3天;p=0.02)。
- SCA组术后球囊扩张较少(17.9% vs 26.7%,p=0.03),全身麻醉更多(99.0% vs 89.6%,p<0.001)。
- 手术时间无差异(57.8 ± 45.3 vs 57.5 ± 32.1分钟,p=0.94),VARC I定义的手术成功率无差异(p=0.89)。
- 30天或1年事件率相似,SCA组有起搏器植入更少的趋势。
临床怎么用
- 对于不适合TF入路的患者,SCA可作为首选的次要入路。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Iliofemoral arterial disease can preclude transfemoral (TF) transcatheter aortic valve replacement (TF-TAVR). Transthoracic access by direct aortic or a transapical approach imparts a greater risk of complications and death than TF access. We hypothesized that subclavian/axillary arterial (SCA) access offers equivalent risks and outcomes as TF access. METHODS: The outcomes of 202 patients from the CoreValve (Medtronic, Minneapolis, MN) United States Pivotal Trial Program treated with SCA access were propensity matched with patients treated with TF access and analyzed. RESULTS: Matching was successful, with no significant baseline differences in the SCA group and the TF group, except the SCA group had more past or present smokers (79.2% vs 61.4%, p < 0.001) and fewer patients with anemia requiring transfusion (18.5% vs 27.5%, p = 0.04). SCA patients experienced a significantly longer time from enrollment to procedure (8.6 ± 19.1 vs 5.3 ± 6.3 days; p = 0.02), likely the result of case planning. Significant differences in procedural outcomes include less post-TAVR balloon dilation (17.9% vs 26.7%, p = 0.03) and more general anesthesia (99.0% vs 89.6%, p < 0.001) for the SCA accesses. There were no differences in procedure time (57.8 ± 45.3 vs 57.5 ± 32.1 min, p = 0.94) or Valve Academic Research Consortium I-defined procedure success between groups (p = 0.89). Event rates at 30 days or 1 year were similar, with a trend toward fewer pacemakers with SCA accesses. CONCLUSIONS: Major morbidity and mortality rates SCA-TAVR are equivalent to TF-TAVR. The SCA should be the preferred secondary access site for TAVR because it offers procedural and clinical outcomes comparable to TF-TAVR and applies to most patients who are not TF candidates.
引用
- Gleason TG, Schindler JT, Hagberg RC, et al. Subclavian/Axillary Access for Self-Expanding Transcatheter Aortic Valve Replacement Renders Equivalent Outcomes as Transfemoral. Ann Thorac Surg. 2017. PMID: 29100645. doi:10.1016/j.athoracsur.2017.07.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。